Evofem Biosciences Holds Annual Meeting, Votes on Key Proposals

Evofem Biosciences held its Annual Meeting on November 26, 2025, where stockholders voted on key proposals. Outcomes included the election of four directors, approval of executive compensation, the 2025 Equity Incentive Plan, and a reverse stock split amendment. BPM LLP was ratified as the accounting firm for 2025. These decisions aim to enhance corporate governance and financial structuring. Spark rates EVFM as Underperform due to poor financial performance and challenges, despite a slightly better technical outlook.

Evofem Biosciences Inc. held annual shareholder meeting

Evofem Biosciences Inc. held its Annual Meeting of Stockholders on November 26, 2025. Stockholders elected Kim Kamdar, Ph.D., Colin Rutherford, Lisa Rarick, and Tony O’Brien as directors. They also approved an amendment for a one-time reverse stock split of the company’s common stock at a ratio between 1-for-500 and 1-for-1,500, to be implemented before November 26, 2026.

Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE | EVFM Stock News

Evofem Biosciences announced that Emirates Drug Establishment issued favorable pricing certificates for PHEXX®, a hormone-free contraceptive gel, marking a key step towards its regulatory approval and commercialization in the UAE. Pharma 1 plans to launch PHEXX® in 2026, subject to approval. Pharma 1 holds exclusive rights for Evofem's products in GCC states, aiming to expand into MENA countries. The initiative reflects Evofem's strategy to diversify revenue and provide Emirati women access to hormone-free contraception.

Evofem Biosciences | 8-K: FY2025 Q3 Revenue: USD 4.952 M

Evofem Biosciences Q3 net sales rise

Evofem Biosciences reported a 10% year-over-year increase in Q3 net sales to $5.0 million, with a $1.0 million operating income, reversing a prior year $2.4 million loss. Operating expenses fell 42%, aiding the profit turnaround. The company aims to reduce manufacturing costs by 50% for PHEXX and SOLOSEC, with SOLOSEC submitted for marketing approval in the UAE. No specific financial guidance was provided for future periods.